Referencias►
1.
Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Arch Gen Psychiatry. 1999;56:29 - 36.
2.
Heresco-Levy U, Javitt DC, Ermilov M, et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Br J Psychiatry. 1996;169:610 - 617.
3.
Javitt DC, Balla A, Sershen H, et al. A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors.
Biol Psychiatry. 1999;45:668 - 679.
4.
Javitt DC, Zylberman I, Zukin SR, et al. Amelioration of negative symptoms in schizophrenia by glycine.
Am J Psychiatry. 1994;151:1234 - 1236.
5.
Semba J. Glycine therapy of schizophrenia; its rationale and a review of clinical trials [translated from Japanese].
Nihon Shinkei Seishin Yakurigaku Zasshi. 1998;18:71 - 80.
6.
Potkin SG, Jin Y, Bunney BG, et al. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.
Am J Psychiatry. 1999;156:145 - 147.
7.
Gusev EI, Skvortsova VI, Dambinova SA, et al. Neuroprotective effects of glycine for therapy of acute ischaemic stroke.
Cerebrovasc Dis. 2000;10:49 - 60.
8.
Fries MH, Rinaldo P, Schmidt-Sommerfeld E, et al. Isovaleric acidemia: response to a leucine load after three weeks of supplementation with glycine, L-carnitine, and combined glycine-carnitine therapy.
J Pediatr. 1996;129:449 - 452.
9.
Itoh T, Ito T, Ohba S, et al. Effect of carnitine administration on glycine metabolism in patients with isovaleric acidemia: significance of acetylcarnitine determination to estimate the proper carnitine dose.
Tohoku JExp Med. 1996;179:101 - 109.
10.
de Koning TJ, Duran M, Dorland L, et al. Beneficial effects of L-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency.
Ann Neurol. 1998;44:261 - 265.
11.
File SE, Fluck E, Fernandes C. Beneficial effects of glycine (Bioglycin) on memory and attention in young and middle-aged adults.
J Clin Psychopharmacol. 1999;19:506 - 512.
12.
Sopala M, Schweizer S, Schafer N, et al. Neuroprotective activity of a nanoparticulate formulation of the glycineB site antagonist MRZ 2/576 in transient focal ischaemia in rats.
Arzneimittelforschung. 2002;52:168-74.
13.
Harvey SG, Gibson JR, Burke CA. L-cysteine, glycine and dl-threonine in the treatment of hypostatic leg ulceration: a placebo-controlled study.
Pharmatherapeutica. 1985;4:227 - 230.
14.
Yin M, Ikejima K, Arteel GE, et al. Glycine accelerates recovery from alcohol-induced liver injury.
J Pharmacol Exp Ther. 1998;286:1014 - 1019.
15.
Thurman RG, Zhong Z, von Frankenberg M, et al. Prevention of cyclosporine-induced nephrotoxicity with dietary glycine.
Transplantation. 1997;63:1661 - 1667.
16.
Zhong Z, Arteel GE, Connor HD, et al. Cyclosporin A increases hypoxia and free radical production in rat kidneys: prevention by dietary glycine.
Am J Physiol. 1998;275:F595 - RF604.
17.
Rose ML, Cattley RC, Dunn C, et al. Dietary glycine prevents the development of liver tumors caused by the peroxisome proliferator WY-14,643.
Carcinogenesis. 1999;20:2075 - 2081.
18.
Rose ML, Madren J, Bunzendahl H, et al. Dietary glycine inhibits the growth of B16 melanoma tumors in mice.
Carcinogenesis. 1999;20:793 - 798.
19.
Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Arch Gen Psychiatry. 1999;56:29 - 36.
20.
Tatlisumak T, Takano K, Meiler MR, Fisher M. A glycine site antagonist ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion.
Acta Neurochir Suppl. 2000;76:331-333.
21.
Javitt DC. Management of negative symptoms of schizophrenia.
Curr Psychiatry Rep. 2001;3:413-417.
22.
Evins AE, Fitzgerald SM, Wine L, et al. Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Am J Psychiatry. 2000;157:826-828.